Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
|Articles|August 10, 2021
Pharmacy Clinical Pearl of the Day: Long-acting vs Rapid-acting Insulin
Author(s)Saro Arakelians, PharmD
Depending on the patient needs, the prescriber can prescribe one or both types of insulin.
Advertisement
Clinical Pearl of the Day: Long-acting vs rapid-acting insulin
Explanation
- Long-acting insulins provides coverage for blood sugars for nearly the entire day.
- Rapid-acting insulins provide coverage when blood sugars spikes, as needed for patients with diabetes.
- Depending on the patient needs, the prescriber can prescribe either or both types of insulin for patients with diabetes.
Reference:
Advertisement
Related to this article
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Ramantamig's 93.6% ORR and Outpatient CRS Control
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
5